Twitter   Facebook   e-Newsletters   Podcsts   RSS Feeds   Share

452
Prous Science Drug Data Report

Last Loaded on Web: Monday, April 01, 2013

Last Update To Bluesheet: September 1, 2011

Bluesheet Contents     PDF version

File Description Dialog File Data Geographic Coverage Terms and Conditions Limit Predefined Format Options
Subject Coverage Related Search Aids Special Features Sample Record Sort Rates
Tips Database Content DIALINDEX/OneSearch Categories Basic Index Rank
Print Counterparts Document Types Indexed Contact Additional Indexes Map


File Description [top]

The Prous Science Drug Data Report database provides continuously updated information on more than 65,000 bioactive compounds reported in the print journal Prous Science Drug Data Report since June 1988. Compounds are "followed" from the patent application stage through research and development phases to approval, marketing, and postmarketing periods. Approximately 10,000 records were added to the database each year. The Prous Science Drug Data Report database is a valuable source of up-to-date information for professionals in research, development, management, marketing, licensing, and information sciences within the pharmaceutical industry and for all those interested in this industry activities.



Tips [top]

USE FILE 452

to monitor drugs in the pipeline from preclinical, clinical (phase I, phase II, or phase III) as well as launch, registered, etc., all indexed by development status (ST=).

USE THERAPEUTIC CODES

to choose therapeutic class

     EXPAND TC=10000
      or
     SELECT ANTICONVULSANT/TC

USE FORMAT 13

to display full record except text & literature references with image.

USE FORMAT 19

to display full record with image(s).



Subject Coverage [top]

Fields in the Prous Science Drug Data Report database include:

  • molecular formula
  • chemical names
  • chemical structure
  • company code names
  • generic names and synonyms
  • brand names
  • industrial or other sources
  • licensees
  • activity index numbers and activity classes
  • development phase
  • CAS registry numbers
  • physical data
  • related compounds
  • relevant patent information (titles, inventors, applicants/assignees, patent, and priority numbers)
  • literature references (title, author, source), and concise text describing the compound's biological activity.

The entries in the Prous Science Drug Data Report database are included from information compiled from published and unpublished sources: current literature references (as of June 1, 1995, more than 100,000 are included in the database); patent references (more than 20,000) from 11 different sources; international congresses and symposia (more than 160 anually); scientific contributions; and company communications (from more than 850 companies).


Print Counterparts [top]

  • Prous Science Drug Data Report


Dialog File Data [top]

Dates Covered: June 1, 1988 to February 2011
File Size: 222,239 records
Update Frequency: Closed (Approximately 1,000 records)


Related Search Aids [top]

For addditional information about Chemical Structure searching available in this file, please see CSS



Database Content [top]

  • Complete Text Records
  • Image Output Available


Document Types Indexed [top]

  • Directories


Geographic Coverage [top]

  • International


Geographic Restrictions [top]

  • None


Special Features [top]

  • ERA Available
  • KWIC and HILIGHT Available
  • DIALOG Alert Available
  • Image Output Available
  • Chemical Structure Searching enabled


DialIndex/OneSearch Categories [top]

ACRONYM CATEGORY NAME
BRANDNMS Brand Names
CASREGNO CAS(R) Registry Numbers-Chemical and Medical Files
CHEMSTRC Chemical Structure Search
DRUGDEV Drug Development Pipeline
DRUGDIR Drug Directories
PHARM Pharmacology
PHARMR Pharmacology + RINGDOC-Files
PROUS Prous Science Publishers Files


Contact [top]

Prous Science Drug Data Report is provided by Prous Science Publishers. Questions concerning file content should be directed to:

Prous Science
P.O. Box 540
Barcelona, 08080
Spain
Telephone: +34 93 459 2220
Fax: +34 93 458 1535
E-Mail: service@prous.es


Terms and Conditions [top]

For Dialog's Redistribution and Archive Policy, enter HELP ERA online. The following terms and conditions also apply. (c)2000 J.R. Prous, S.A. All rights reserved. No part of this electronic database may be reproduced, abstracted, or transmitted in any form or by any means--electronic, mechanical, photocopying, recording, or otherwise--without the express written permission of the publisher, J.R. Prous, S.A. While great care has been taken in the preparation of this database, and the publisher has made a reasonable effort to supply complete and accurate information, it does not assume any liability for errors or omissions. J.R. Prous, S.A. makes no warranties, expressed or implied, with respect to the accuracy, quality, validity, or completeness of this database or the information therein or its merchantability or fitness for a particular purpose.


Dialog Standard Terms & Conditions apply.


SAMPLE RECORD [top]

    DIALOG(R)File 452:Prous Science Drug Data Report 
     (c) 2000 J.R. Prous S.A. All rts. reserv. 
     
     00149658 
  AA=   ENTRY NUMBER:  149658 
     COMPOUND TYPE: Preferred 
  /SY, SY=,/NA,NA=    DRUG NAME:     256U87 
                     BW-256U 
                    ValACV 
  /NA,NA=   GENERIC NAME   Valaciclovir (recommended INN) 
                    Valacyclovir (USAN) 
  /TN,TN=   BRAND NAME:    Valtrex (Wellcome, GB, EI) 
  /CN,CN=   CHEM NAME:     L-Valine 2-(2-amino-6-hydroxy-9H-purin-9- 
                    ylmethoxy) ethyl ester 
                    L-Valine 2-(2-amino-6-oxo-1,6-dihydro-9H-purin-9- 
                    ylmethoxy)ethyl ester 
                    L-Valine 2-(guanin-9-ylmethoxy)ethyl ester 
  MF=   FORMULA:       C13H20N6O4 
  RN=   CAS REG. NO.:  124832-26-4 
                    124832-27-5 (monoHCl salt) 
  ST=   DEVEL. PHASE:  Launched (1995) 
  /LO, LO=   ORIGINATOR:    Wellcome 
  /LI, LI=   LICENSEE:      Hoechst 
                    Theraplix 
  RE=   RELATED ENTRY: 151566 (secondary) 
     
  /TX   ACTION:        Antiviral agent, ester of the antiherpetic 
     compound acyclovir, with better water solubility and 
     gastrointestinal absorption after oral administration than 
     acyclovir, without substantial decline of the antiviral activity 
     in vitro. In rats, urinary recovery as acyclovir was 63 % of the 
     dose for the title compound and 15 % for acyclovir. Another 
     specifically claimed amino acid ester of the known purine 
     nucleoside is: 151566. (Drug Data Report, Vol. 11, No. 7, p. 592, 
     1989) 
     
     ACTION:        Acyclovir prodrug, ester with L-valine that was 
     found to berapidly converted to the parent compound in studies in 
     rats and primates; due to good results in these studies, it was 
     advanced to clinical testing in man. In single-dose studies in 
     healthy volunteers , it gave peak acyclovir values of 0.8 +/- 0.1 
     and 5.6 +/- 2.4 mcg/ml at 24 h after administration of 100 or 
     1000 mg, respectively. Mean t1/2 at all doses was approx. 28 h. 
     After multiple doses in volunteers (250,500 or 1000 mg four times 
     daily for 11 days), pharmacokinetic parameters were similar to 
     those after single dosing. Due to the compound'senhanced delivery 
     of acyclovir and its favorable pharmacokinetic profile, it has 
     been moved to phase II studies. (Drug Data Report, Vol. 13, No. 
     11, p. 998, 1991) 
     
     PREV. PUB. IN: Drugs of the Future, Vol. 18, No. 7, p. 619, 1993 
     
     PATENTS: 
     
  /TI   THERAPEUTIC NUCLEOSIDES 
  AU=   AUTHOR(s):     Beauchamp, L.M., Krenitsky, T.A. 
  PA=   APPLICANT(s):  Wellcome Found. 
  PC=, PN=   FAMILY:        20978      [AU 8820978  Austria, February 16, 
                    1989 
                    308065     [EP 308065   European Patent Office, 
                    March 22, 1989 
                    596542     [EP 596542   European Patent Office, 
                    May 11, 1994 
                    1-068373   [JP 1068373  Japan, March 14, 1989 
                    3-115284   [JP 3115284  Japan, May 16, 1991 
                    4,957,924  [US 4957924  United States of America, 
                    September 18, 1990 
                    5,061,708  [US 5061708  United States of America, 
                    October 29, 1991 
  AN=   PRIORITY:      8719367    [GB 8719367  Great Britain, August 15, 
                    1987 
                    8725939    [GB 8725939  Great Britain, November 
                    5, 1987 
     
  /RF, RF=   REFERENCES: 
     
     Blum, M.R. et al., "Single and multiple-dose pharmacokinetics of 
     a new acyclovir prodrug, 256U87, in healthy volunteers", 31st 
     Intersci Conf Antimicrob Agents Chemother (Sept 29-Oct 2, 
     Chicago) 1991, Abst 763 
     
     De Miranda, P. and Burnette, T.C., "Metabolism and 
     pharmacokinetics of the acyclovir prodrug BW 256U87 in cynomolgus 
     monkeys", Antivir Res 1992, 17(Suppl. 1): Abst 19 
     
     Burnette, T.C. and De Miranda, P., "Metabolic disposition of BW 
     256U87, the L-valyl ester of acyclovir, in the rat", Antivir Res 
     1992, 17(Suppl. 1): Abst 142 
     Beauchamp, L. et al., "Amino acid esters of acyclovir as oral 
     prodrugs", Antivir Res 1992, 17(Suppl. 1): Abst 143 
     
                                (...) 
     
     "Valtrex - Wellcome's successor to Zovirax - approved", Wellcome 
     plc News Release 1995, January 27 
     
     Wellcome plc Annual Report 1994 


BASIC INDEX [top]

SEARCH
SUFFIX
DISPLAY
CODE
FIELD NAME
INDEXING
SELECT EXAMPLES
None None All Basic Index Fields Word S ANTIVIRAL
/CN CN Chemical Name2 Word S VALINE(W)2/CN
/CO CO Company Name1,2 Word S WELLCOME/CO
/LI LI Licensee2 Word S THERAPLIX/LI
/LO LO Originator2 Word S WELLCOME/LO
/NA NA Chemical Name2,3 Word S VALACV/NA
/RF RF Cited References2 Word S ACYCLOVIR/RF
/SY SY Drug Name2,4 Word S VALACYCLOVIR/SY
/TC TC Therapeutic Class Text5 Word S ANTIVIRAL/TC
/TI PI Patent Title Word S NUCLEOSIDES/TI
/TN TN Brand Name2 Word S VALTREX/TN
/TX TX Text Word S PURINE(W)NUCLEOSIDE/TX

1 Includes Licensee (/LI, LI=) and Originator (/LO, LO=).

2 Searchable in the Basic Index and in the Additional Indexes.

3 Includes Chemical Name, Laboratory Code, Brand Name, and Generic Drug Name.

4 Includes Laboratory Code,Brand Name, and Generic Drug Name.

5 Also searchable with /DE.


ADDITIONAL INDEXES [top]

SEARCH
PREFIX
DISPLAY
CODE
FIELD NAME
INDEXING
SELECT EXAMPLES
AA= AA Prous Entry Number Phrase S AA=149658
AC= AC Application Country Phrase S AC=GB
AN= PI Patent Application/Priority Number Phrase S AN=GB 8719367
AU= PI Patent Inventor Name Phrase S AU=BEAUCHAMP L?
None AZ DIALOG Accession Number
CN= CN Chemical Name2 Phrase S CN=L-VALINE 2?
CO= CO Company Name1,2 Phrase S CO=WELLCOME?
FS= FS File Segment Phrase S FS=ACTIVELY INVESTIGATED
None IM Image
LI= LI Licensee2 Phrase S LI=THERAPLIX
LO= LO Originator2 Phrase S LO=WELLCOME
MF= MF Molecular Formula Phrase S MF=C13H20N6O4
NA= NA Chemical Name2,3 Phrase S NA=VALACV
PA= PI Patent Applicant/Assignee Word
& Phrase
S PA=(WELLCOME(W)FOUND?)
S PA=WELLCOME?
S PA=WELLCOME?
None PC Preferred Compound
PC= PI Patent Country Phrase S PC=JP
PN= PI Patent Number Phrase S PN=EP 308065
None PP Properties
None PU Previously Published In
RE= RE Related Entry Number Phrase S RE=151566
RF= RF Cited References2 Word S RF=(BURNETTE(W)T(W)C)
RN= RN CAS(R) Registry Number Phrase S RN=124832-26-4
RT= None Record Type Phrase S S1 AND RT=IMAGE
ST= ST Development Status Phrase S ST=PREREGISTERED
SY= SY Drug Name2,4 Phrase S SY=VALACYCLOVIR
TC= TC Therapeutic Class Code/Class Name Phrase S TC=71000
TN= TN Brand Name2 Phrase S TN=VALTREX
UC= None Update-changed records Phrase S UC=9999
UD= None Update Phrase S UD=9999


LIMIT [top]

SUFFIX FIELD NAME EXAMPLES
/PREF Compound Type -- Preferred S S2/PREF
/SEC Compound Type -- Secondary S S2/SEC


SORT [top]

SORTABLE FIELDS EXAMPLES
CO, LO, NA, RN, ST, SY SORT S1/ALL/LO,D
PRINT S5/5/1-24/LO


RANK [top]

RANK FIELDS EXAMPLES
All phrase- and numeric-indexed fields in the Additional Indexes can be ranked. RANK LO
RANK LI S4


MAP [top]

MAP FIELDS EXAMPLES
AN, NA, PN, PREF, PREFSEC, RN, SEC MAP ANYY TEMP S2
MAP RN TEMP S1


USER-DEFINED FORMAT OPTIONS [top]

Display codes listed in the Search Options tables can be used to customize output. TYPE S3/CO, NA/1-5
PRINT S2/AN, RN/ALL


PREDEFINED FORMAT OPTIONS [top]

NO.
DIALOGWEB
FORMAT
RECORD CONTENT
1 -- DIALOG Accession Number
2 -- Full Record except patents and literature references
3 Short Full Record except text, patents and literature references
4 -- Full Record with Tagged Fields
5 Medium Full Record except literature references
6 -- Entry Number, Compound Type and Therapeutic Class
7 -- Full Record except literature references
8 Free Entry Number, Compound Type and Therapeutic Class
9 Long Full Record
12 -- Full Record except patents and literature references with image.
13 -- Full Record except text, patents and literature references with image.
14 -- Full Record--tagged format with image
15 -- Full Record except literature references with image
16 -- Entry Number, Compound Type and Therapeutic Class with image
17 -- Full Record except literature references with image
18 -- Entry Number, Compound Type and Therapeutic Class with image
19 Full Full Record with image(s)
K -- KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats


DIRECT RECORD ACCESS [top]

FIELD NAME EXAMPLES
If the accession number of a specific record is known, it can be used to display the record directly. TYPE 00149658/5
DISPLAY 00149658/AA,NA
PRINT 00149658/9


Rates [top]

Rates For File: Prous Science Drug Data Report[452]
Cost per DialUnit:                $12.39
Cost per minute:                   $3.52
Rank Elements                      $0.00

Format    Types   Prints
     1    $0.00    $0.00
     2   $17.00   $17.00
     3   $10.00   $10.00
     4   $28.00   $28.00
     5   $20.00   $20.00
     6    $0.00    $0.00
     7   $20.00   $20.00
     8    $0.00    $0.00
     9   $28.00   $28.00
    12   $20.00   $20.00
    13   $13.00   $13.00
    14   $30.00   $30.00
    15   $25.00   $25.00
    16    $3.50    $3.50
    17   $25.00   $25.00
    18    $3.50    $3.50
    19   $30.00   $30.00
KWIC95    $2.75       NA
KWIC96    $2.75       NA

REDIST/COPY Multiplier Table:

      Range      Multiplier
        1-2       1.00
       3-25       1.50
     26-100       3.00
    101-200       4.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00

ARCHIVE Multiplier Table:

      Range      Multiplier
       1-25       1.50
     26-200       3.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00
---------------------------------

A charge of $20.00 applies to each CSS (Chemical Structure Search)
whether searching in one database or across multiple databases.  The
standard output charges for each database apply to any documents
retrieved.
[top]



All contents Copyright © Dialog, LLC. All rights reserved.
If you have any questions about, problems with, or corrections for our Web site,
please contact Customer Service for assistance.